One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to MOTS-c in 台灣. US research-market identity.

Current source route

MOTS-c in 台灣

Direct answer / 台灣

Can you buy MOTS-c in 台灣?

US research-market identity

This record resolves a name to the US laboratory research catalog tracked by Peptide Local. It does not establish authorization, lawful supply, medical use, or availability in the selected destination.

  1. 01
    Resolve the nameResearch price board
  2. 02
    Check 台灣Research price board
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordUS research-market identity

What MOTS-c resolves to

This record resolves a name to the US laboratory research catalog tracked by Peptide Local. It does not establish authorization, lawful supply, medical use, or availability in the selected destination.

Evidence lane
Research price board
Current record
5 of 7 rows in stock
Checked
Jul 23, 2026
MOTS cMitochondrial open reading frame peptide
Destination record產品許可與機構身分必須分開查證

What 台灣 still has to prove

本指南提供台灣胜肽、胜肽藥品、減重藥物與研究材料的逐步查證方式。先在衛生福利部食品藥物管理署許可證資料庫核對特定產品,再以衛生福利部醫事查詢系統確認藥局或醫療機構目前是否開業,避免把相同名稱、繁體中文頁面或新台幣價格誤當成核准與合法供應的證明。查證時應保留許可證字號、機構代碼、法定名稱、地址與查詢日期,讓每項網路聲明都能回到可重複檢查的紀錄。

Comparison mode
TWD / TFDA 許可證與衛福部醫事機構紀錄
Price coverage
尚無符合發布標準的台灣賣方價格表
Guide updated
2026年7月18日
Evidence coverageRouting records only

No compound-specific official record is attached to this exact pairing yet. That is an evidence gap, not proof of approval, prohibition, availability, or absence. Use the country guide and official product and seller routes to verify the exact offer.

Open the full country check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail